Compare ATCH & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATCH | DARE |
|---|---|---|
| Founded | 2022 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.5M | 33.4M |
| IPO Year | 2024 | 2014 |
| Metric | ATCH | DARE |
|---|---|---|
| Price | $0.19 | $2.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $1.00 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 1.4M | 186.6K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | ★ $2,807,885.00 |
| Revenue This Year | $84.47 | $2,115.12 |
| Revenue Next Year | $39.32 | $122.62 |
| P/E Ratio | $4.05 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.14 | $1.27 |
| 52 Week High | $1.92 | $9.19 |
| Indicator | ATCH | DARE |
|---|---|---|
| Relative Strength Index (RSI) | 38.35 | 47.20 |
| Support Level | $0.19 | $1.94 |
| Resistance Level | $0.21 | $2.23 |
| Average True Range (ATR) | 0.01 | 0.16 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 15.74 | 59.04 |
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.